NCT07541287 · Jade Biosciences, Inc.
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
What this study is about
This where both patients and doctors know the treatment given Phase 2 study will characterize the safety and effectiveness of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
View original scientific description
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent
- eGFR ≥ 30 mL/min/1.73 m2
- Biopsy-confirmed primary IgAN
- Receiving stable and maximally tolerated doses of either ACEi or ARB as per standard of care (SoC) and applicable guidelines for at least 12 weeks prior to the initial screening visit, with no intention to alter the dose or discontinue treatment, unless medically necessary
- UPCR ≥ 0.75 g/g
- Willing to provide written informed consent
- Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, and other study procedures
- Willing and able to comply with contraceptive and lifestyle requirements
Exclusion criteria
- Secondary forms of IgAN
- Known or suspected coexisting Chronic Kidney Disease (CKD) other than IgAN
- Known or suspected rapidly progressive glomerulonephritis (RPGN)
- Evidence of pathological findings in the kidney biopsy in addition to IgAN (eg, minimal change disease, diabetic kidney disease, membranous nephropathy, focal segmental glomerulosclerosis, or lupus nephritis); hypertensive vascular changes are acceptable
- Known or suspected primary or secondary immunodeficiency disorder
- Evidence of tuberculosis infection at screening
- Any chronic infectious disease
- Any acute infectious disease at time of screening
- Received bone marrow, hematologic stem cell transplantation, or a solid organ transplant, including kidney
- Known or suspected alcohol or drug abuse
- Any clinically significant and/or unstable or uncontrolled medical condition as assessed by the investigator
- Malignancy within the past 5 years; nonmelanoma skin cancer and curatively treated cervical carcinoma in situ are allowed Other protocol-defined inclusion/exclusion criteria may apply
Where
- Chula Vista, California
- Arvada, Colorado
- Denver, Colorado
- Orlando, Florida
- Pembroke Pines, Florida
- Houston, Texas
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 7, 2026 · Source of record for eligibility and locations